Abstract
The dementia epidemic is likely to expand worldwide as the aging population continues to grow. A better understanding of the molecular mechanisms that lead to dementia is expected to reveal potentially modifiable risk factors that could contribute to the development of prevention strategies. Alzheimer’s disease is the most prevalent form of dementia. Currently we only partially understand some of the pathophysiological mechanisms that lead to development of the disease in aging individuals. In this study, Switch Miner software was used to identify key switch genes in the brain whose expression may lead to the development of Alzheimer’s disease. The results indicate that switch genes are enriched in pathways involved in the proteasome, oxidative phosphorylation, Parkinson’s disease, Huntington’s disease, Alzheimer’s disease and metabolism in the hippocampus and posterior cingulate cortex. Network analysis identified the krupel like factor 9 (KLF9), potassium channel tetramerization domain 2 (KCTD2), Sp1 transcription factor (SP1) and chromodomain helicase DNA binding protein 1 (CHD1) as key transcriptional regulators of switch genes in the brain of AD patients. These transcriptions factors have been implicated in conditions associated with Alzheimer’s disease, including diabetes, glucocorticoid signaling, stroke, and sleep disorders. The specific pathways affected reveal potential modifiable risk factors by lifestyle changes.
Introduction
Dementia affects over 50 million people worldwide, approximately 67% of which have Alzheimer’s disease (AD) [1]. By 2050 it is predicted that as many as 152 million people may have dementia [1]. Unfortunately, there remains no cure for AD and only four drugs have been approved for treatment that manages symptoms of dementia in some patients. We currently do not completely understand the cause of AD, but there is strong data to support the involvement of the proteins amyloid and tau. In AD patients, amyloid-ß and hyperphosphorylated tau are produced abundantly in the brain. Amyloid-ß forms inter-neuronal plaques that disrupt cell function, whereas tau forms intra-neuronal neurofibrillary tangles that block intracellular transport. Risk factors for AD include genetics (i.e. APOE epsilon 4 carrier), biology (i.e. aging and gender), and environmental factors (i.e. glucose and cholesterol metabolism, inflammation and oxidative stress) related to lifestyle choices or accidents (i.e. diet, exercise, smoking, education and head trauma).
Plaques and tangles may appear in the brain 18 years before the onset of symptoms [2]. Initially plaques and tangles form in the hippocampus (HIP) and entorhinal cortex (EC) of the temporal lobe, which are involved in learning and memory [3]. In addition to the HIP and EC, metabolic and pathological differences have been found in the middle temporal gyrus (MTG), posterior cingulate cortex (PCC), and superior frontal gyrus (SFG) of AD patients [4–24]. The primary visual cortex (VCX) usually does not show disease-related neurodegeneration [25, 26]. Recently, laser capture microdissection (LCM) was used to select neurons in regions of the brain affected in AD patients and healthy elderly controls. Gene expression profiling of the neurons identified changes that occur in the development and pathogenesis of AD [19, 26]. One striking finding from these studies is that AD patients have significantly reduced expression of mitochondrial transport chain genes in the PCC, MTG and HIP compared to controls [27].
The key events in AD development remain unknown, but gene expression studies on postmortem brain tissue are expected to reveal pathways that are dysregulated in patients. Recently SWItch Miner (SWIM) software has been developed that combines gene expression data with topological properties of correlation networks to reveal major changes in cellular phenotype that are at the root of biological processes [28]. In SWIM, the Pearson correlation coefficient between the expression of two genes is used to build co-expression networks. RNA transcripts are the nodes of the network and connections between nodes are made if the expression of the genes is significantly correlated or anti-correlated. Clustering algorithms are used to identify disease modules. SWIM analysis identifies “switch genes” that may be fundamental to a disease. SWIM has been used to identify switch genes involved in the transformation of glioblastomas from stem-like to the differentiated state [29] and reprogramming in grapevine development from immature to mature growth [30]. The use of SWIM could be expanded to the study of chronic diseases in order to reveal key players that lead to disease development.
In this study, we have used SWIM to identify genes whose expression is associated with drastic changes in the brain of AD patients. The results show that the switch genes in the HIP and PCC regions of the brain that are affected in AD patients are enriched in proteasome, oxidative phosphorylation, metabolic, Parkinson’s disease, Huntington’s disease, and Alzheimer’s disease pathways.
Methods
Database mining
The NCBI GEO database (https://www.ncbi.nlm.nih.gov/gds) and ArrayExpress database (https://www.ebi.ac.uk/arrayexpress/) were searched on June 3, 2019 for studies in which gene expression data was available from laser-captured neurons in the brain of Alzheimer’s patients (Fig 1). The NCBI GEO database was queried using the search terms Alzheimer’s, brain, neuron and "Homo sapiens"[Organism]) for the study types expression profiling by array and expression profiling by high-throughput sequencing. 44 studies were identified, 21 were brain-specific studies and 4 had data from laser-captured neurons (GSE28146, GSE66333, GSE5281, GSE4757). The ArrayExpress database was searched using the keywords Alzheimer’s, Homo sapiens, and transcription and 74 studies were identified, 27 of these studies were brain-specific and 3 studies had data from laser-captured neurons (GSE28146, GSE29652, and GSE4757).
SWIM analysis to identify switch genes
Raw data from the expression arrays was imported into SWIM. The SWIM algorithm is comprised of several steps shown in Fig 2 [31]. In the pre-processing phase, genes that are not expressed or only slightly expressed are removed. In the filtering phase, the fold-change limit was set between 2–4 and genes that were not significantly expressed differently between AD patients compared to controls are removed. The False Discovery Rate method was used to correct for multiple tests [32] and then a Pearson correlation analysis was used to build a co-expression network of genes differentially expressed between AD patients and controls. In step 4, the k-means algorithm was then used to identify communities within the network [33]. To determine the number of clusters, SWIM uses Scree plot, which allows replicating the clustering many times with a new set of initial cluster centroid positions, and for each replicate the k-means algorithm performs iterations until the minimum of the sum of the squared error (SSE) function is reached. The cluster configuration with the lowest SSE values among the replicates is designated as the number of clusters. The heat cartography map is built using a clusterphobic coefficient Kπ, which measures external and internal node connections, and the global within-module degree Zg, which measures the extent each node is connected to others in its own community. When Zg exceeds 5 a node it is considered a hub. The average Pearson correlation coefficient (APCC) between the expression profiles of each node and its nearest neighbors is used to build the heat cartography map. Using APCC, three types of hubs may be identified. Date hubs show low positive co-expression with their partners (low APCC), party hubs show high positive co-expression (high APCC), and nodes that have negative APCC values are called fight-club hubs [28]. In the final step of SWIM analysis, switch genes are identified that are a subset of the fight-club hubs that interact outside of their community. Switch genes are characterized as not being a hub in their own cluster (low Zg <2.5), having many links outside their own cluster (Kπ >0.8, when Kπ is close to 1 most of its links are external to its own module), and having a negative average weight of incident links (APCC <0) [28].
The switch genes are the set of genes that interact outside their own community, are not in local hubs and are mainly anti-correlated with their interaction partners. After the switch genes are identified, KEGG pathway analysis was conducted to see if the results imply a relationship to a disease. The random set of genes is chosen from the identified nodes from above. The analysis is performed by studying the effect on the network connectivity of removing different types of nodes by decreasing degree. The total number of nodes to be removed must be equal to the total number of switch genes and the cumulative node deletion is carried out by type (i.e., total hubs, party hubs, date hubs, fight-club hubs, switch genes, and randomly chosen nodes).
Pathway analysis
Entrez gene identifiers from the SWIM analysis were imported into the Database for Annotation, Visualization and Integrated Discovery (DAVID) (https://david.ncifcrf.gov/) which uses singular enrichment analysis [34, 35]. The functional annotation tool was used to select Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis. The biological functions of KEGG charts were enriched with p < .05.
Transcription factor analysis
Entrez gene identifiers from the SWIM analysis were imported into NetworkAnalyst for network analysis of transcription factors [36]. In NetworkAnalyst, we used the transcription factor and gene target data derived from the ENCODE ChIP-seq data. Transcription factor analysis in NetworkAnalyst uses the BETA Minus Algorithm in which only peak intensity signal < 500 and the predicted regulatory potential score <1 is used. Transcription factors were ranked according to network topology measurements including degree and betweenness centrality.
Results
In order to identify gene expression changes in the brain that may lead to the transition from a healthy aging brain to that of AD patient, we used the SWIM algorithm. The Array Express and NCBI databases were searched to identify studies that contained expression data from postmortem brain tissue of AD patients and age-matched controls (Fig 1). LCM neuron studies (GSE28146, GSE29652, GSE4757, GSE66333 and GSE5281) and several microarrays with samples from brain sections were identified. SWIM analysis was conducted on each of these datasets. In all of the brain section studies and four of the LCM studies, the p values were not sufficiently robust to complete SWIM analysis. Only GSE5281 had data with sufficiently robust p values for the analysis to be completed.
The characteristics of the participants in the GSE5281 study [19, 26, 27] are presented in Table 1. Brain samples from a total of 22–23 participants (10 AD patients and 12–13 controls, depending on the brain region). The average age of the participants was 83 years old. The controls were matched as closely as possible for age at death and mean education level. The AD patients had a Braak stage ranging from III-IV [26].
Table 1. Characteristics of study participants.
GSE5281 | Entorhinal | cortex | |
Variable | HC | AD | P Value |
Number of participant | 13 | 10 | |
Age, mean (SD) | 80.3 (9.2) | 85.6 (6.3) | 0.13 |
Female/male, No (% male) |
3/10 (76) | 6/4 (40) | 0.07 |
GSE5281 | Hippocampus | ||
Variable | HC | AD | P Value |
Number of participant | 13 | 10 | |
Age, mean (SD) | 79.6 (9.4) | 77.8 (5.7) | 0.6 |
Female/male, No (% male) |
3/10 (76) | 4/6 (60) | 0.38 |
GSE5281 | Mid | temporal | gyrus |
Variable | HC | AD | P Value |
Number of participant | 12 | 10 | |
Age, mean (SD) | 80.1 (9.8) | 79.1 (6.4) | 0.76 |
Female/male, No (% male) |
4/8 (67) | 6/10 (63) | 0.82 |
GSE5281 | Posterior | cingulate | cortex |
Variable | HC | AD | P Value |
Number of participant | 13 | 10 | |
Age, mean (SD) | 79.8 (9.4) | 77.5 (6.2) | 0.56 |
Female/male, No (% male) |
4/9 (69) | 3/6 (67) | 0.90 |
GSE5281 | Superior | frontal | gyrus |
Variable | HC | AD | P Value |
Number of participant | 13 | 10 | |
Age, mean (SD) | 79.3 (10.2) | 79.2 (7.5) | 0.97 |
Female/male, No (% male) |
4/7 (64) | 10/13 (67) | 0.69 |
GSE5281 | Primary | visual | cortex |
Variable | HC | AD | P Value |
Number of participant | 13 | 10 | |
Age, mean (SD) | 79.9 (7) | 80.2 (6.7) | 0.38 |
Female/male, No (% male) |
3/9 (75) | 8/11 (58) | 0.33 |
Gene expression data from laser-captured neurons from HIP, EC, MTG, PCC, SFG and VCX was imported into SWIM. The data for EC using a linear fold-change of 3 is presented in Fig 3. The samples that were filtered out in step 2 of the analysis are depicted as grey bars in Fig 3A, whereas those that are retained for further analysis are shown in red. In Fig 3B the correlation communities are identified. The fight-club hubs are depicted in R4 in blue and are negatively correlated in expression with their interaction partner. A heat map of the expression of the switch genes, step 5, is shown in Fig 3C. After the switch genes are identified, the data is analyzed further to assess robustness. The data in Fig 3D indicates that fight-club hubs differ from date and party hubs and the switch genes are significantly different that random. The switch genes identified in the EC are listed in S1 Table.
The data for HIP using a linear fold-change of 3 is presented in Fig 4. The samples that are retained for further analysis are depicted in red in Fig 4A, the correlation communities are identified in Fig 4B and the fight-club hubs are depicted in R4 in blue. A heat map of the expression of the switch genes, is shown in Fig 4C. The data indicates that fight-club hubs differ from date and party hubs and the switch genes are significantly different that random, Fig 4D. The switch genes identified in the HIP are listed in S2 Table.
The data for MTG using a linear fold-change of 4 is presented in Fig 5. The samples that are retained are depicted in red, Fig 5A and the correlation communities are identified in Fig 5B with the fight-club hubs depicted in R4 in blue. A heat map of the expression of the switch genes is presented in Fig 5C. The data indicates that fight-club hubs differ from date and party hubs and the switch genes are significantly different that random, Fig 5D. The switch genes identified in the MTG are listed in S3 Table.
The data for PCC using a linear fold-change of 4 is presented in Fig 6. The samples that are retained for further analysis are depicted in red, Fig 6A, the correlation communities are identified in Fig 6B with the fight-club hubs depicted in R4 in blue. A heat map of the expression of the switch genes, step 5, is shown in Fig 6C. The data indicates that fight-club hubs differ from date and party hubs and the switch genes are significantly different that random, Fig 6D. The switch genes identified in the PCC are listed in S4 Table.
For SFG, initially the fold-change was set at 3 and SWIM was not able to identify any switch genes. We then set the linear fold-change of 2.5 and the data obtained from SWIM analysis is presented in Fig 7. The samples that are retained for further analysis are depicted in red, Fig 7A, the correlation communities are identified in Fig 7B and very few fight-club hubs were found. A heat map of the expression of the switch genes, step 5, is shown in Fig 7C. The data indicates that fight-club hubs differ from date and party hubs, but the switch genes differ only slightly from random, Fig 7D. The switch genes identified in the SFG are listed in S5 Table.
For VCX, initially the fold-change was set at 3 and SWIM was not able to identify any switch genes. We then set the linear fold-change at 2 and the data obtained from SWIM analysis is presented in Fig 8. The samples that are retained for further analysis are depicted in red in Fig 8A and the correlation communities are identified in Fig 8B. The fight-club hubs are depicted in R4 in blue. A heat map of the expression of the switch genes, step 5, is shown in Fig 8C. The data indicates that fight-club hubs do not differ measurably from date and party hubs, but the switch genes are significantly different than random, Fig 8D. The switch genes identified in the VCX are listed in S6 Table.
A Venn diagram analysis and UpSetR plot analysis of the switch genes identified in each brain region is shown in Fig 9 and S7 Table. The order of brain regions which have the largest number of switch genes to the least number is HIP>PCC>EC>MTG>VCX>SFG. The regions that had the largest number of unique switch genes to that which had the least is HIP>EC>PCC>MTG>VCX>SFG. The PCC shares 53 switch genes with the HIP (S7 Table). Interestingly, the EC shares only 1 switch gene with HIP and one with the PCC. Most of the EC switch genes are unique for that region of the brain.
Pathway analysis of the switch genes was performed in order to identify functions. In the HIP the majority of the disrupted pathways were involved with metabolism, specifically glutamine, glutamate, steroid, arginine, pyruvate and amino acids metabolism (Fig 10). Changes in gene expression involved with oxidative phosphorylation, RNA transport and the spliceosome are enriched in switch genes. The switch genes of the HIP are also enriched in Parkinson’s, Alzheimer’s and Huntington’s disease pathways. The PCC switch genes are also enriched in metabolic and Parkinson’s, Alzheimer’s and Huntington’s disease pathways (Fig 11). The switch genes dysregulated pathways shared in the PCC and HIP are the proteasome, oxidative phosphorylation and metabolism (S1 Fig and S7 Table). The switch genes in the EC, MTG, VCX and SFG are not enriched in any particular pathways.
In order to identify key transcriptional regulators of the switch genes from the different brain regions, a transcription factor analysis was performed using NetworkAnalyst [36]. Network analysis was performed using the brain regions with the greater number of switch genes, the HIP and PCC. Network analysis revealed that switch genes identified in the HIP region were regulated by the transcription factors, krupel like factor 9 (KLF9), and potassium channel tetramerization domain 2 (KCTD2), whereas those from the PCC region were regulated by KLF9, Sp1 transcription factor (SP1), and chromodomain helicase DNA binding protein 1 (CHD1). As noted above, KLF9 was shared between the HIP and PCC brain regions (S3 and S4 Figs).
Discussion
In this study we used SWIM analysis to identify key genes in regions of the brain known to show metabolic and pathological differences in AD patients compared to healthy aging individuals including the HIP, PCC, EC, MTG, and SFG. For comparison we also analyzed gene expression data from the VCX, which usually does not show disease-related neurodegeneration. Transcription data from laser-captured neurons was interrogated to identify switch genes. The results indicate that changes in gene expression in both the HIP and PCC may alter brain function by disrupting metabolism, oxidative phosphorylation, and the proteasome (S1 Fig).
Previous studies have shown that the PCC and HIP are affected in AD patients [12]. The PCC shows a reduction in glucose metabolism in early AD and has the largest abnormal positron emission tomography scans of cognitively normal late-middle age individuals who carry the APOE epsilon 4 allele [24, 38, 39]. The HIP shows neurofibrillary tangles in AD patients [12, 14–16]. In addition, energy metabolism genes showed lower expression levels in the PCC and HIP in AD patients compared to controls [27].
In contrast to our study, a previous study that analyzed gene expression changes using the same microarray data found that cellular physiological processes, transport, metabolism and cellular localization were pathways affected across most brain regions including the PCC, HIP, EC, and MTG [26]. The unique aspect of the SWIM algorithm that most likely explains the difference in the results is that it includes fight-club hubs that are negatively correlated with their interaction partners. Therefore, although there is a dysregulation of gene expression that leads to pathways affected in multiple brain regions in AD patients, our data indicate that key switch gene changes that alter significant pathways are present mainly in in the PCC and HIP.
Our results also showed that switch genes in the EC, MTG, VCX and SFG are not enriched in any particular pathways. This suggests that these brain regions may be more resistant to key switch events that cause neurodegeneration compared to the PCC and HIP regions. Similar to our findings, the earlier study that analyzed the GSE5281 data found that the SFG and VCX areas, which are affected in later stages of AD, are relatively neuroprotected and capable of resisting disease pathology [26].
Caberlotto and colleagues used network analysis of AD-related genes to conclude that metabolism-associated processes including insulin and fatty acid metabolism underlie the development of AD [40]. In this study, seed genes associated with AD were obtained from the same transcriptomic data we used (microarray GSE5281). In addition, they used single nucleotide polymorphism data from AD, molecular targets of AD drugs and AD genes present in the Online Mendelian Inheritance in Man database. We compared the switch genes identified in our study to the AD-related seed genes identified by Caberlotto and colleagues and the results indicate that many of the switch genes were the same as the seed genes, especially in the HIP and PCC strongly suggesting that dysregulation of metabolic processes are key events important to the development of AD (S2 Fig and S8 Table).
Network analysis of the switch genes in the HIP and PCC brain regions identified several transcription factors relevant to the pathogenesis of AD. For example, network analysis identified KLF9 and KCTD2 as the main regulatory transcription factors of the HIP switch genes. Recently, Cui and colleagues demonstrated that KLF9 promotes the expression of peroxisome proliferator-activated receptor γ coactivator 1α (PGC1 α) resulting in hepatic gluconeogenesis and suggested that KLF9 may be responsible for the glucocorticoid therapy-induced diabetes [41]. In this context, diabetes has been extensively associated with an increased risk for AD [42]. Moreover, glucocorticoid overexposure has been associated with cognitive decline, amyloid beta misprocessing and ultimately, the development of AD [43, 44]. Given the involvement of KLF9 in glucose homeostasis and glucocorticoid signaling, its potential as a therapeutic target for AD warrants further investigation.
In addition to KLF9, KCTD2 was another key transcription factor regulating the HIP switch genes. Genome wide association studies identified KCTD2 as a shared susceptibility gene between AD and ischemic stroke [45, 46]. Interestingly, KCTD2 may play a role in sleep regulation [47, 48] and sleep disturbances have been linked to the development of AD [49].
Similarly, network analysis identified KLF9, SP1 and CHD1 as central regulators of PCC switch genes. Dysregulation of SP1 in AD has been documented in several studies. For instance, SP1 mRNA was upregulated in brains of both human and transgenic AD model mice [50]. Inhibition of SP1 function in a transgenic AD model mice increased memory deficits suggesting that it may be a useful therapeutic target [51]. Another important transcription factor, CHD1, is involved in TDP-43 mediated neurodegeneration [52]. Recently, Chd1 has been found to play a role in learning and memory in mice [53]. Furthermore, Chd1 knockdown in mouse embryonic stem cells mimicked high fat diet and aging-induced gene expression changes [54]. Collectively, the transcription factors identified in this study are involved in processes related to the pathogenesis of AD and thus may be important therapeutic targets.
There is a potential caveat that should be kept in mind when interpreting the results from this study. Although several possible gene expression datasets were identified, only one study achieved the high stringent p-values required for the SWIM analysis. Therefore, the results presented herein may be specific for this dataset and not of AD in general. Nonetheless, the pathways and transcription factors identified in this study have been associated with AD by other investigations. Future studies will seek to confirm the validity of these findings in an independent microarray.
Conclusions
This study provides novel insights into the key switch events that occur in the HIP and PCC involved in the transformation from a healthy aging brain to that of an AD patient. The majority of the pathways in the HIP and PCC that are altered in AD patients are involved with metabolism including disruption of glutamine, glutamate, steroid, arginine, pyruvate and amino acids metabolism. In addition, some of the transcriptional regulators of the switch genes are involved in glucose homeostasis, glucocorticoid signaling, sleep regulation, and memory. Targeting these transcription factors may provide novel therapeutics for AD.
Supporting information
Acknowledgments
This study was funded by the National Institute on Aging (NIA) grant number R01AG062176 to JAP. The NIA had no role in the design, data collection and analysis, decision to publish or preparation of this manuscript.
Q Regulating Systems, LLC and NeuroHub Analytics, LLC provided support in the form of salaries for authors J.P.Q. and J.A.S., but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Data Availability
All relevant data are within the manuscript and its Supporting Information files.
Funding Statement
J.A.P. received funding from National Institute on Aging (NIA) (https://www.nia.nih.gov/) grant number R01AG062176. The NIA had not role in the design, data collection and analysis, decision to publish or preparation of this manuscript. NeuroHub Analytics, LLC. and Q Regulating Systems, LLC provided support in the form of salaries for authors J.P.Q. and J.A.S., but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific roles of these authors are articulated in the ‘author contributions’ section.
References
- 1.Patterson C. World Alzheimer Report 2018. The state of the art of dementia research: New frontiers London, UK: 2018.
- 2.Rajan KB, Wilson RS, Weuve J, Barnes LL, Evans DA. Cognitive impairment 18 years before clinical diagnosis of Alzheimer disease dementia. Neurology. 2015;85(10):898–904. 10.1212/WNL.0000000000001774 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 3.Serrano-Pozo A, Frosch MP, Masliah E, Hyman BT. Neuropathological alterations in Alzheimer disease. Cold Spring Harb Perspect Med. 2011;1(1):a006189 10.1101/cshperspect.a006189 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 4.Angelie E, Bonmartin A, Boudraa A, Gonnaud PM, Mallet JJ, Sappey-Marinier D. Regional differences and metabolic changes in normal aging of the human brain: proton MR spectroscopic imaging study. AJNR Am J Neuroradiol. 2001;22(1):119–27. . [PMC free article] [PubMed] [Google Scholar]
- 5.Beach TG, Walker R, McGeer EG. Patterns of gliosis in Alzheimer's disease and aging cerebrum. Glia. 1989;2(6):420–36. 10.1002/glia.440020605 . [DOI] [PubMed] [Google Scholar]
- 6.Bliss TV, Collingridge GL. A synaptic model of memory: long-term potentiation in the hippocampus. Nature. 1993;361(6407):31–9. 10.1038/361031a0 . [DOI] [PubMed] [Google Scholar]
- 7.Bobinski M, de Leon MJ, Convit A, De Santi S, Wegiel J, Tarshish CY, et al. MRI of entorhinal cortex in mild Alzheimer's disease. Lancet. 1999;353(9146):38–40. 10.1016/s0140-6736(05)74869-8 . [DOI] [PubMed] [Google Scholar]
- 8.Bouras C, Hof PR, Giannakopoulos P, Michel JP, Morrison JH. Regional distribution of neurofibrillary tangles and senile plaques in the cerebral cortex of elderly patients: a quantitative evaluation of a one-year autopsy population from a geriatric hospital. Cereb Cortex. 1994;4(2):138–50. 10.1093/cercor/4.2.138 . [DOI] [PubMed] [Google Scholar]
- 9.Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. 1991;82(4):239–59. 10.1007/bf00308809 . [DOI] [PubMed] [Google Scholar]
- 10.Braak H, Braak E. The human entorhinal cortex: normal morphology and lamina-specific pathology in various diseases. Neurosci Res. 1992;15(1–2):6–31. 10.1016/0168-0102(92)90014-4 . [DOI] [PubMed] [Google Scholar]
- 11.Davies L, Wolska B, Hilbich C, Multhaup G, Martins R, Simms G, et al. A4 amyloid protein deposition and the diagnosis of Alzheimer's disease: prevalence in aged brains determined by immunocytochemistry compared with conventional neuropathologic techniques. Neurology. 1988;38(11):1688–93. 10.1212/wnl.38.11.1688 . [DOI] [PubMed] [Google Scholar]
- 12.de Leon MJ, George AE, Stylopoulos LA, Smith G, Miller DC. Early marker for Alzheimer's disease: the atrophic hippocampus. Lancet. 1989;2(8664):672–3. 10.1016/s0140-6736(89)90911-2 . [DOI] [PubMed] [Google Scholar]
- 13.Du AT, Schuff N, Zhu XP, Jagust WJ, Miller BL, Reed BR, et al. Atrophy rates of entorhinal cortex in AD and normal aging. Neurology. 2003;60(3):481–6. 10.1212/01.wnl.0000044400.11317.ec [DOI] [PMC free article] [PubMed] [Google Scholar]
- 14.Fox NC, Warrington EK, Stevens JM, Rossor MN. Atrophy of the hippocampal formation in early familial Alzheimer's disease. A longitudinal MRI study of at-risk members of a family with an amyloid precursor protein 717Val-Gly mutation. Ann N Y Acad Sci. 1996;777:226–32. 10.1111/j.1749-6632.1996.tb34423.x . [DOI] [PubMed] [Google Scholar]
- 15.Frisoni GB, Laakso MP, Beltramello A, Geroldi C, Bianchetti A, Soininen H, et al. Hippocampal and entorhinal cortex atrophy in frontotemporal dementia and Alzheimer's disease. Neurology. 1999;52(1):91–100. 10.1212/wnl.52.1.91 . [DOI] [PubMed] [Google Scholar]
- 16.Hyman BT, Van Hoesen GW, Damasio AR, Barnes CL. Alzheimer's disease: cell-specific pathology isolates the hippocampal formation. Science. 1984;225(4667):1168–70. 10.1126/science.6474172 . [DOI] [PubMed] [Google Scholar]
- 17.Ibanez V, Pietrini P, Alexander GE, Furey ML, Teichberg D, Rajapakse JC, et al. Regional glucose metabolic abnormalities are not the result of atrophy in Alzheimer's disease. Neurology. 1998;50(6):1585–93. 10.1212/wnl.50.6.1585 . [DOI] [PubMed] [Google Scholar]
- 18.Jack CR Jr., Petersen RC, Xu Y, O'Brien PC, Smith GE, Ivnik RJ, et al. Rate of medial temporal lobe atrophy in typical aging and Alzheimer's disease. Neurology. 1998;51(4):993–9. 10.1212/wnl.51.4.993 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 19.Liang WS, Dunckley T, Beach TG, Grover A, Mastroeni D, Walker DG, et al. Gene expression profiles in anatomically and functionally distinct regions of the normal aged human brain. Physiol Genomics. 2007;28(3):311–22. 10.1152/physiolgenomics.00208.2006 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 20.Mielke R, Herholz K, Grond M, Kessler J, Heiss WD. Clinical deterioration in probable Alzheimer's disease correlates with progressive metabolic impairment of association areas. Dementia. 1994;5(1):36–41. . [DOI] [PubMed] [Google Scholar]
- 21.Morris JC, Price JL. Pathologic correlates of nondemented aging, mild cognitive impairment, and early-stage Alzheimer's disease. J Mol Neurosci. 2001;17(2):101–18. . [DOI] [PubMed] [Google Scholar]
- 22.Price JL, Davis PB, Morris JC, White DL. The distribution of tangles, plaques and related immunohistochemical markers in healthy aging and Alzheimer's disease. Neurobiol Aging. 1991;12(4):295–312. 10.1016/0197-4580(91)90006-6 . [DOI] [PubMed] [Google Scholar]
- 23.Rogers J, Morrison JH. Quantitative morphology and regional and laminar distributions of senile plaques in Alzheimer's disease. J Neurosci. 1985;5(10):2801–8. . [DOI] [PMC free article] [PubMed] [Google Scholar]
- 24.Small GW, Ercoli LM, Silverman DH, Huang SC, Komo S, Bookheimer SY, et al. Cerebral metabolic and cognitive decline in persons at genetic risk for Alzheimer's disease. Proc Natl Acad Sci U S A. 2000;97(11):6037–42. 10.1073/pnas.090106797 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 25.Metsaars WP, Hauw JJ, van Welsem ME, Duyckaerts C. A grading system of Alzheimer disease lesions in neocortical areas. Neurobiol Aging. 2003;24(4):563–72. 10.1016/s0197-4580(02)00134-3 . [DOI] [PubMed] [Google Scholar]
- 26.Liang WS, Dunckley T, Beach TG, Grover A, Mastroeni D, Ramsey K, et al. Altered neuronal gene expression in brain regions differentially affected by Alzheimer's disease: a reference data set. Physiol Genomics. 2008;33(2):240–56. 10.1152/physiolgenomics.00242.2007 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 27.Liang WS, Reiman EM, Valla J, Dunckley T, Beach TG, Grover A, et al. Alzheimer's disease is associated with reduced expression of energy metabolism genes in posterior cingulate neurons. Proc Natl Acad Sci U S A. 2008;105(11):4441–6. 10.1073/pnas.0709259105 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 28.Fiscon G, Conte F, Farina L, Paci P. Network-Based Approaches to Explore Complex Biological Systems towards Network Medicine. Genes (Basel). 2018;9(9). 10.3390/genes9090437 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 29.Fiscon G, Conte F, Licursi V, Nasi S, Paci P. Computational identification of specific genes for glioblastoma stem-like cells identity. Sci Rep. 2018;8(1):7769 10.1038/s41598-018-26081-5 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 30.Palumbo MC, Zenoni S, Fasoli M, Massonnet M, Farina L, Castiglione F, et al. Integrated network analysis identifies fight-club nodes as a class of hubs encompassing key putative switch genes that induce major transcriptome reprogramming during grapevine development. Plant Cell. 2014;26(12):4617–35. 10.1105/tpc.114.133710 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 31.Paci P, Colombo T, Fiscon G, Gurtner A, Pavesi G, Farina L. SWIM: a computational tool to unveiling crucial nodes in complex biological networks. Sci Rep. 2017;7:44797 10.1038/srep44797 ; PubMed Central PMCID: PMC5357943. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 32.Benjamini Y, Hochberg Y. Controlling the false discovery rate: A practical and powerful approach to multiple testing. J R Stat Soc Ser B Stat Methodol. 1995:289–300. [Google Scholar]
- 33.Hartigan J, Wong M. Algorithm AS 136: A k-means clustering algorithm. J R Stat Soc Ser B Stat Methodol. 1979:100–8. [Google Scholar]
- 34.Dennis G Jr., Sherman BT, Hosack DA, Yang J, Gao W, Lane HC, et al. DAVID: Database for Annotation, Visualization, and Integrated Discovery. Genome Biol. 2003;4(5):P3 . [PubMed] [Google Scholar]
- 35.Huang DW, Sherman BT, Tan Q, Kir J, Liu D, Bryant D, et al. DAVID Bioinformatics Resources: expanded annotation database and novel algorithms to better extract biology from large gene lists. Nucleic Acids Res. 2007;35(Web Server issue):W169–75. 10.1093/nar/gkm415 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 36.Xia J, Gill EE, Hancock RE. NetworkAnalyst for statistical, visual and network-based meta-analysis of gene expression data. Nat Protoc. 2015;10(6):823–44. 10.1038/nprot.2015.052 . [DOI] [PubMed] [Google Scholar]
- 37.Lex A, Gehlenborg N, Strobelt H, Vuillemot R, Pfister H. UpSet: Visualization of Intersecting Sets. IEEE Trans Vis Comput Graph. 2014;20(12):1983–92. Epub 2015/09/12. 10.1109/TVCG.2014.2346248 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 38.Minoshima S, Giordani B, Berent S, Frey KA, Foster NL, Kuhl DE. Metabolic reduction in the posterior cingulate cortex in very early Alzheimer's disease. Ann Neurol. 1997;42(1):85–94. 10.1002/ana.410420114 . [DOI] [PubMed] [Google Scholar]
- 39.Reiman EM, Chen K, Alexander GE, Caselli RJ, Bandy D, Osborne D, et al. Correlations between apolipoprotein E epsilon4 gene dose and brain-imaging measurements of regional hypometabolism. Proc Natl Acad Sci U S A. 2005;102(23):8299–302. 10.1073/pnas.0500579102 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 40.Caberlotto L, Lauria M, Nguyen TP, Scotti M. The central role of AMP-kinase and energy homeostasis impairment in Alzheimer's disease: a multifactor network analysis. PLoS One. 2013;8(11):e78919 10.1371/journal.pone.0078919 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 41.Cui A, Fan H, Zhang Y, Zhang Y, Niu D, Liu S, et al. Dexamethasone-induced Kruppel-like factor 9 expression promotes hepatic gluconeogenesis and hyperglycemia. J Clin Invest. 2019;130:2266–78. 10.1172/JCI66062 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 42.de la Monte SM, Wands JR. Alzheimer's disease is type 3 diabetes-evidence reviewed. J Diabetes Sci Technol. 2008;2(6):1101–13. 10.1177/193229680800200619 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 43.Canet G, Chevallier N, Zussy C, Desrumaux C, Givalois L. Central Role of Glucocorticoid Receptors in Alzheimer's Disease and Depression. Front Neurosci. 2018;12:739 10.3389/fnins.2018.00739 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 44.Ouanes S, Popp J. High Cortisol and the Risk of Dementia and Alzheimer's Disease: A Review of the Literature. Front Aging Neurosci. 2019;11:43 10.3389/fnagi.2019.00043 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 45.Boada M, Antunez C, Ramirez-Lorca R, DeStefano AL, Gonzalez-Perez A, Gayan J, et al. ATP5H/KCTD2 locus is associated with Alzheimer's disease risk. Mol Psychiatry. 2014;19(6):682–7. 10.1038/mp.2013.86 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 46.Traylor M, Adib-Samii P, Harold D, Alzheimer's Disease Neuroimaging I, International Stroke Genetics Consortium UKYLSDNAr, Dichgans M, et al. Shared genetic contribution to Ischaemic Stroke and Alzheimer's Disease. Ann Neurol. 2016;79(5):739–47. 10.1002/ana.24621 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 47.Li Q, Kellner DA, Hatch HAM, Yumita T, Sanchez S, Machold RP, et al. Conserved properties of Drosophila Insomniac link sleep regulation and synaptic function. PLoS Genet. 2017;13(5):e1006815 10.1371/journal.pgen.1006815 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 48.Pirone L, Smaldone G, Esposito C, Balasco N, Petoukhov MV, Spilotros A, et al. Proteins involved in sleep homeostasis: Biophysical characterization of INC and its partners. Biochimie. 2016;131:106–14. 10.1016/j.biochi.2016.09.013 . [DOI] [PubMed] [Google Scholar]
- 49.Ju YE, Lucey BP, Holtzman DM. Sleep and Alzheimer disease pathology—a bidirectional relationship. Nat Rev Neurol. 2014;10(2):115–9. 10.1038/nrneurol.2013.269 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 50.Citron BA, Dennis JS, Zeitlin RS, Echeverria V. Transcription factor Sp1 dysregulation in Alzheimer's disease. J Neurosci Res. 2008;86(11):2499–504. 10.1002/jnr.21695 . [DOI] [PubMed] [Google Scholar]
- 51.Citron BA, Saykally JN, Cao C, Dennis JS, Runfeldt M, Arendash GW. Transcription factor Sp1 inhibition, memory, and cytokines in a mouse model of Alzheimer's disease. Am J Neurodegener Dis. 2015;4(2):40–8. [PMC free article] [PubMed] [Google Scholar]
- 52.Berson A, Sartoris A, Nativio R, Van Deerlin V, Toledo JB, Porta S, et al. TDP-43 Promotes Neurodegeneration by Impairing Chromatin Remodeling. Curr Biol. 2017;27(23):3579–90 e6. 10.1016/j.cub.2017.10.024 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 53.Schoberleitner I, Mutti A, Sah A, Wille A, Gimeno-Valiente F, Piatti P, et al. Role for Chromatin Remodeling Factor Chd1 in Learning and Memory. Front Mol Neurosci. 2019;12:3 10.3389/fnmol.2019.00003 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 54.Green CD, Huang Y, Dou X, Yang L, Liu Y, Han JJ. Impact of Dietary Interventions on Noncoding RNA Networks and mRNAs Encoding Chromatin-Related Factors. Cell Rep. 2017;18(12):2957–68. 10.1016/j.celrep.2017.03.001 . [DOI] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.
Supplementary Materials
Data Availability Statement
All relevant data are within the manuscript and its Supporting Information files.